Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis.

Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy - 1 Oct 2016

Miyazaki Ryoichi, Miyagi Kyoko

Abstract excerpt

The prevalence of anti-hepatitis C virus (HCV)antibodies is higher in hemodialysis patients than in the general population, and several studies have reported poor vital prognosis in HCV-infected dialysis patients because infection with HCV is not only the cause of cirrhosis and hepatocellular carcinoma, but also a risk factor for cardiovascular disease. Although sustained virologic response (SVR) is achievable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbamates
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Isoquinolines

Share to Pyrrolidines

Share to Renal Dialysis

Share to Sulfonamides

Share to Valine

Source

Identifiers

PMID: 27098678
DOI: 10.1111/1744-9987.12407

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis.PMID 27098678Read ↗

Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.Semantic proximity Read ↗

Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection.Semantic proximity Read ↗

The Efficacy of the Direct-Acting Antiviral Combination in Hemodialysis Patients With Chronic Hepatitis C Virus Genotype 1 InfectionSemantic proximity Read ↗

Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients.Semantic proximity Read ↗

Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.Semantic proximity Read ↗

Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.Semantic proximity Read ↗

Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?Semantic proximity Read ↗

Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C.Semantic proximity Read ↗

Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.Semantic proximity Read ↗

Treatment of chronic hepatitis C with sofosbuvir in a hemodialysis patient: a case report.Semantic proximity Read ↗

Safety and Efficacy of Direct-acting Antiviral Therapies for Chronic HCV Infection in Hemodialysis Patients.Semantic proximity Read ↗

Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.